drugset / Trial / NCT04699721

Clinical Study of Neoadjuvant Chemotherapy and Immunotherapy Combined With Probiotics in Patients With Resectable NSCLC

NCT04699721

Phase 2 Active not recruiting 60 enrolled Xiangya Hospital of Central South University
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the safety and effect of neoadjuvant chemotherapy and immunotherapy combined with probiotics for early resectable NSCLC patients.

Timeline

Start
2020-07-01
Primary completion
2027-09
Completion
2027-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Bifico Other / unclassified 4 unknown Oral
Subject Carboplatin Small molecule 5 unknown
Subject Nivolumab Monoclonal antibody 4.5 mg/kg
Subject Paclitaxel Small molecule 260 mg/m2